Advertisement

Topics

Amgen: Tax reforms stoke $300m investment in next-gen US biomanufacturing plant

08:29 EST 2 Feb 2018 | BioPharma-Reporter

Amgen has announced plans for a US biomanufacturing facility, similar to its flexible and single-use Singapore plant, as part of $3.5bn freed through tax reforms.

Original Article: Amgen: Tax reforms stoke $300m investment in next-gen US biomanufacturing plant

NEXT ARTICLE

More From BioPortfolio on "Amgen: Tax reforms stoke $300m investment in next-gen US biomanufacturing plant"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...